tigilanol tiglate

DRUG4 trials

Sponsors

QBiotics Group Limited

Conditions

Head and Neck CancerMelanomaSoft Tissue Sarcoma

Phase 1

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

TerminatedNCT04834973

QBiotics Group LimitedMelanoma

Start: 2021-05-07End: 2022-07-12Updated: 2023-04-18

Phase 2

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

TerminatedNCT05234437

QBiotics Group LimitedMelanoma

Start: 2022-03-09End: 2022-07-18Updated: 2023-04-19

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Active, not recruitingNCT05608876

QBiotics Group LimitedHead and Neck Cancer

Start: 2022-11-03End: 2026-08-31Updated: 2025-08-07

A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

RecruitingNCT05755113

QBiotics Group LimitedSoft Tissue Sarcoma

Start: 2023-04-13End: 2027-06-01Target: 40Updated: 2026-03-12

Related Papers

1091 Tigilanol Tiglate is a small molecule oncolytic that induces immunogenic cell death and promotes immune cell infiltration into human tumors

Regular and Young Investigator Award Abstracts2023-10-31

1121 Tigilanol tiglate is a naturally occurring small molecule oncolytic that effectively ablates tumors via intratumoural injection and can enhance response to immune checkpoint blockade

Regular and Young Investigator Award Abstracts2022-11-01